IPHA
Innate Pharma
NASDAQ: IPHA · HEALTHCARE · BIOTECHNOLOGY
$1.48
+5.71% today
Updated 2026-04-29
Market cap
$138.87M
P/E ratio
—
P/S ratio
15.42x
EPS (TTM)
$-0.64
Dividend yield
—
52W range
$1 – $3
Volume
0.0M
Innate Pharma (IPHA) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
+16.1%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
—
Most recent quarter
When is the next earnings report?
Reporting date
December 31, 2025
Consensus EPS estimate
$-0.14
Fiscal period ending
2025-12-31
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-5.2%
Last 1 reports
Positive reaction rate
0%
0 of 1 quarters
Largest single-day move
-5.2%
2025-11-13
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2025-11-13 | $-0.14 | -1.6% | $1.92 | $1.82 | -5.2% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.14 | — | — | $1.11M | — |
| 2025-09-30 | $-0.14 | $-0.14 | -1.6% | — | — |
| 2025-06-30 | — | $-0.30 | — | $4.86M | -60.6% |
| 2025-03-31 | $-0.40 | $-0.30 | +25.0% | $276000.00 | -98.3% |
| 2024-12-31 | $-0.40 | $-0.30 | +25.0% | — | — |
| 2024-09-30 | $0.00 | $0.00 | — | — | — |
| 2024-06-30 | $-0.38 | $0.00 | +100.0% | $12.35M | -65.1% |
| 2024-03-31 | $0.00 | $0.00 | — | $16.56M | -17.6% |
| 2023-12-31 | $-0.41 | $0.00 | +100.0% | $21.44M | — |
| 2023-09-30 | $0.00 | $0.00 | — | $10.72M | — |
| 2023-06-30 | $-0.14 | $0.02 | +114.3% | $35.34M | — |
| 2023-03-31 | $0.00 | $0.00 | — | $20.10M | — |
Frequently asked questions
When does Innate Pharma report next earnings?
Innate Pharma (IPHA) is scheduled to report earnings on December 31, 2025. The consensus EPS estimate is $-0.14.
Has Innate Pharma beaten earnings estimates?
Innate Pharma has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, with an average EPS surprise of +16.1% over the last 3 quarters.
How does IPHA stock react to earnings?
IPHA stock has moved an average of -5.2% in the trading day following earnings over its last 1 reports, with positive reactions in 0% of those quarters.